←
OncoAlert128,159 posts
OncoAlert avatar

OncoAlert

@OncoAlert

🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°

◷ Joined March 2019▧ 6,088 Photos and videos
OncoAlert avatar
OncoAlert@OncoAlert·Nov 16

🎸 #UromigosLIVE 2026: the conversation on X 📊 THE FINAL NUMBERS Coverage by @OncoAlert 🚨 Nashville | Nov 13–14 🌍 5.7M potential reach 💬 3,200 posts & mentions 🔥 4,200 engagements 🇺🇸 USA 59.5% 🇮🇹 Italy 13.3% 🇪🇸 Spain 10% 🇮🇳 India 4.6% 🇯🇵 Japan 🇩🇪 Germany 🇸🇦 Saudi Arabia 🇦🇪 UAE 🇳🇱 Netherlands 🏆 Thank you to every #UroVoice who amplified the meeting, and to Tom & Brian for an unforgettable #UromigosLIVE 🙏 WE ARE ALL OncoAlert 🌐 Source: Talkwalker, X, Nov 10–16 @Uromigos @tompowles1 @brian_rini @shilpaonc @nataliagandur @PGrivasMDPhD @weoncologists @neerajaiims @Dr_Aggen @NazliDizman @montypal @AmandaNizamMD @scserendipity1 @DrKarineTawagi @CParkMD @TiansterZhang @OncoReporte @dralsharm @crisbergerot @UroDocAsh @RenoHemonc

Post attachment
Sumanta K. Pal, MD, FASCO avatar
⟳ OncoAlert retweeted
Sumanta K. Pal, MD, FASCO@montypal·1h

A million thanks to @TiansterZhang for the kind invite to the deliver the 2026 Pamela Hearn Isom Lecture in honor of Eugene P. Frenkel, MD. Dr. Frenkel was recruited to @UTSWMedCenter in 1962 & established the Division of Hematology/Oncology. He discovered the link between B12 def & myelin sheath dysfunction, with consequent neurologic dysfunction. Excited to discuss the #microbiome & #cancer and cite collaborations w @hmcarthur @utswcancer (via our co-mentee @AlexisLeVee @UCLAHealthJCCC). Also honored to pay homage to the terrific ongoing #kidneycancer investigation at @utswcancer from @TiansterZhang, @JBrugarolas, @QingZhangLab, @SuzanneColeMD, @HHammersMD & others. Join tomorrow, 11/19/26 at 4 pm CT at the link below: events.utsouthwestern.edu/ev…

Post attachment
IJGC avatar
⟳ OncoAlert retweeted
IJGC@IJGConline·23m

We need your participation! The Lancet Commission on #OvarianCancer is an international forum of experts on ovarian cancer: 🔍 Screening 🛡️ Prevention 🧬 Biology 💊 Therapeutics 📈 Survivorship 👤 Patient experience Over 3 years, it will produce a Commission report to guide future policy. More info: bit.ly/3VHEbLf @pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @Suvidyasingh20 @ohadfeld

Post attachment
Dana-Farber’s Breast Oncology Center avatar
⟳ OncoAlert retweeted
Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc·1h

Join Dr. Harold Burstein (@DrHBurstein) and Dr. Erica Mayer (@elmayermd) for a timely discussion on the evolving treatment landscape of ER+/HER2− #MetastaticBreastCancer. They explore recent FDA approvals informed by the #EMBER3 (imlunestrant), #SERENA6 (camizestrant), and, most recently, #evERA (giredestrant plus everolimus) clinical trials, highlighting their clinical significance and implications for treatment sequencing, biomarker-guided decision-making, and patient care. 🎧Listen to our Breast Cancer Insights podcast on all streaming platforms! danafarber-breastoncology.bu… @stolaney1 @OncoAlert @PTarantinoMD #MBC #BreastCancerInsights #BreastCancer

Post attachment
Niklas Klümper avatar
⟳ OncoAlert retweeted
Niklas Klümper@niklas_kluemper·3h

🧬 Is the tumor microenvironment more conserved than the tumors themselves? Fascinating new study in @Nature! Across 42 cancer types and >2,000 human & mouse tumor samples, Januszyk et al. identify conserved stromal and immune transcriptional programs across organs and species. An exciting step towards understanding shared mechanisms of immune evasion and therapy resistance. Could pan-cancer TME signatures help us develop better biomarkers for immunotherapy—even across different tumor entities? Importantly, shared transcriptional programs ≠ identical therapeutic vulnerabilities. 🔗 doi.org/10.1038/s41586-026-1… Explore the atlas: tmeatlas.stanford.edu @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Post attachment
Niklas Klümper avatar
⟳ OncoAlert retweeted
Niklas Klümper@niklas_kluemper·4h

From diagnosis to destruction! 🎯 Congrats Ken @ProfKHerrmann on your outstanding ESMO Keynote Lecture and accompanying editorial in @Annals_Oncology 👏 Well deserved! Radioligand therapy is rapidly emerging as a new pillar of precision oncology—turning molecular imaging into targeted treatment. Exciting to see nuclear medicine moving to the very center of modern oncology. sciencedirect.com/science/ar… @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Post attachment
Dr Rishabh Jain avatar
⟳ OncoAlert retweeted
Dr Rishabh Jain@DrRishabhOnco·5h

🚨 ESMO 2026 UPDATE: The treatment landscape of oncogene-driven NSCLC is changing! 🫁 New ESMO Living Guideline recommendations bring several important updates: 🔹 EGFR: Amivantamab + chemotherapy after osimertinib; Dato-DXd in later lines. 🔹 ALK: Lorlatinib preferred, especially with brain metastases. Ensartinib added as a 1L option. 🔹 ROS1: Taletrectinib and zidesamtinib enter treatment algorithms. 🔹 HER2 TKD mutations: Zongertinib or sevabertinib recommended in 1L. 🔹 EGFR exon20ins: Sunvozertinib after platinum chemotherapy. 🔹 NRG1 fusion: Zenocutuzumab after prior therapy. 🔹 High cMET overexpression: Telisotuzumab vedotin after 1L treatment. 💡 The big shift: Molecular profiling is increasingly important not just at diagnosis, but also at progression. 📖 Annals of Oncology, 2026 | Hendriks et al. @esmo_open @myesmo @asco @oncoalert #NSCLC #LungCancer #PrecisionOncology #ESMO26 Full paper link in comment below ⬇️.

Post attachmentPost attachmentPost attachmentPost attachment
Kristina Jankovic, MD avatar
⟳ OncoAlert retweeted
Kristina Jankovic, MD@JankovicK·5h

Join us for The OncoAlert 5k at #SABCS26🏃🏃‍♀️ Sign up 👇 oncoalert.m-pages.com/5zQf2o…

A warm welcome to #SABCS26 🇺🇸 and our Homecoming—the #OncoAlert5K in San Antonio, TX! 🏃‍♀️🏃‍♂️ SIGN UP 👇 oncoalert.m-pages.com/5zQf2o… All are welcome! Join us in front of The Alamo at 7 AM on Thursday, December 10, 2026. We can’t wait to see colleagues from around the world come together for the #OncoAlert5K! 🇺🇸 @weoncologists · @OncoAlert · @Icro_Meattini · @matteolambe · @aftimosp · @E_de_Azambuja · @DrSGraff · @ErikaHamilton9 · @hoperugo · @stolaney1 · @BianchiniGP · @kevinpunie · @ElisaAgostinett · @to_be_elizabeth · @GaiaGriguolo · @JankovicK · @raalbany · @JavierCortesMD · @JaniceTNBCmets · @Prof_Nadia_H · @LoiSher · @jamecancerdoc · @Lucarecco · @guiandri76 · @nataliagandur

0:13
Enrique Grande avatar
⟳ OncoAlert retweeted
Enrique Grande@drenriquegrande·5h

🇪🇺 The future of clinical trials in Europe: Are we ready to rethink the rules? Europe has the science, the talent, and the patients. But are we creating the right environment to lead the next generation of oncology clinical trials? Thrilled to be part of the 5th San Raffaele Urologic Oncology Retreat in Milan on December 4th, brilliantly led by @AndreaNecchi. Looking forward to a particularly timely multidisciplinary debate on reconsidering the EU clinical trials framework, bringing together perspectives from the EMA, the US, the UK, and leading European clinical investigators. @scocmem @shilpaonc @g_procopio_ We need clinical trials that are faster, smarter, more accessible, and truly patient-centered, without compromising scientific rigor or patient safety. The future of European clinical research will not be defined only by the treatments we discover, but also by our ability to bring innovation to patients. Looking forward to an inspiring and thought-provoking discussion with outstanding colleagues! #GURetreat26 #ClinicalTrials #GUOncology #ClinicalResearch #Innovation @OncoAlert @urotoday @IBCG_BladderCA

Post attachment